Outcome of the Board Meeting held on 30.05.2025

Revenue declinedNet loss reportedNegative operating cash flowResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.6%Reaction day

₹11.82

prior close

₹11.15

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.1%-3.6% vs market

Pharmaceuticals peers, median of 147sector-0.1%-3.5% vs sector

On the reaction day the stock moved 3.6 pts less than Nifty Microcap 250 and 3.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+2.9

10m

+0.4

15m

+2.1

30m

+2.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-3.6+0.1-3.6-0.1-3.5

Next day

-4.1-0.2-4.0-0.2-4.0

-8.9+0.3-9.2-0.2-8.6

-6.5+0.9-7.4+0.0-6.5

-5.6+0.8-6.4+0.0-5.6

-4.1+2.2-6.2+0.6-4.7

-3.0+3.4-6.4+1.4-4.5

15d

-6.5-0.8-5.7-2.9-3.6

-2.7+2.9-5.6+0.3-3.0

-3.6+0.8-4.4-0.4-3.2

-10.3+0.0-10.3-3.2-7.1

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 147Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The Board approved audited financial results for Q4 and FY ended 31.03.2025 with an unmodified (unqualified) opinion from auditors M/s. Ramanathan & Rao. On a standalone basis, revenue collapsed from Rs. 353.16 lakh in FY24 to just Rs. 35.67 lakh in FY25, and the company swung from a small profit of Rs. 2.51 lakh to a loss of Rs. 164.02 lakh. On a consolidated basis (including US and Bahrain subsidiaries), revenue fell from Rs. 3,587.85 lakh to Rs. 2,261.25 lakh (~37% decline), while the net loss widened sharply from Rs. 167.55 lakh to Rs. 508.02 lakh. Mrs. Ankita Mathur was appointed as Executive Director for three years at a remuneration of Rs. 1,00,000/month, and Mr. Sushant Mohan Lal moved from Executive to Non-Executive Director.

Likely market impact

Despite a clean audit opinion, the results are deeply negative for shareholders — revenue has collapsed and losses have widened significantly both standalone and consolidated, with negative operating cash flow of Rs. 981.82 lakh on a consolidated basis. The stock is likely to face selling pressure, though the appointment of a new Executive Director signals an attempt to revive the business.